• Salona Global Medical Device Corporation (SGMD) has announced a bought-deal private placement for gross proceeds of $4,004,000
  • The company will issue 7,280,000 units at a price of $0.55 per unit
  • Salona has also provided the underwriters with an over-allotment option for additional gross proceeds of up to $600,600
  • The offering is expected to close on or about February 15, 2022
  • Salona Global Medical Device Corp is a U.S.-based medical device company
  • Salona Global Medical Device Corporation (SGMD) opened trading at C$0.55 per share

Salona Global Medical Device Corporation (SGMD) has announced a bought-deal private placement for gross proceeds of $4,004,000.

The company will issue 7,280,000 units at a price of $0.55 per unit. Each unit will consist of one common share and one share purchase warrant. Each warrant can be exercised for one additional share at a price of $0.70 for up to three years following the closing of the offering.

Salona has also provided the underwriters with the option to purchase up to an additional 1,092,000 units, for additional gross proceeds of up to $600,600.

Net proceeds will be used for working capital and general corporate purposes.

The offering is expected to close on or about February 15, 2022.

Salona Global Medical Device Corp is a U.S.-based medical device company. 

Salona Global Medical Device Corporation (SGMD) opened trading at C$0.55 per share.

More From The Market Online

Buzz on the Bullboards: Oil shock, biotech breakthroughs and new tech

Global equities lurched from rally to rout since the U.S.–Israel strikes on Iran ignited a regional war and shutdown of the Strait of Hormuz.

Quit smoking with psychedelics? A new frontier for treatment — and investors

A new Johns Hopkins study found that a single dose of psilocybin, combined with therapy, helped smokers stay cigarette free at six months.

New bladder cancer drug may sharpen radiation’s aim

Theralase Technologies proves that its Rutherrin drug holds the potential to enhance radiation against non-muscle invasive bladder cancer.